Cat. No. | Product name | CAS No. |
DC65242 |
MK-0159
Featured
MK-0159 is a CD38 enzymatic inhibitor. Mice treated with MK-0159 show strong protection from myocardial damage upon cardiac I/R injury compared to those treated with NAD+ precursors (nicotinamide riboside) or another CD38 inhibitor. |
2641484-61-7 |
DC65243 |
RP-6306
Featured
RP-6306 is a PKMYT1 inhibitor extracted from patent WO2021195781A1 compound 182. RP-6306 can be used for the research of cancer. |
2719793-90-3 |
DC65244 |
Dalzanemdor
Featured
Dalzanemdor (SAGE-718) is a N-methyl-D-aspartate (NMDA) receptor positive allosteric modulator. |
1629853-48-0 |
DC65245 |
BI-4142
Featured
BI-4142 is a potent, highly selective and orally active HER2 inhibitor with an IC50= 5 nM. BI-4142 showed efficacy against HER2 exon 20 insertion-driven tumors, while preserving EGFR wt signaling. |
2682003-36-5 |
DC65246 |
GST-HG131
Featured
GST-HG131 is a specific inbihitor of hepatitis B virus (HBV) surface antigen, belongs to dihydrobenzopyridooxazepine (DBP) series. GST-HG131 exhibits excellent and specific HBV antigens inhibition with EC50 of 28.2 nM (HBsAg) and 16.0 nM (HBeAg), respectively, but also it is safety for animal. |
2270215-69-3 |
DC65247 |
AZD-1656
Featured
AZD-1656 is a glucokinase (GK) activator potentially for the treatment of type 2 diabetes and obesity. |
919783-22-5 |
DC65248 |
JNJ-64264681
Featured
JNJ-64264681 is a covalent, irreversible BTK inhibitor with potent whole blood activity and exceptional kinome selectivity. JNJ-64264681 demonstrated excellent oral efficacy in both cancer and autoimmune models with sustained in vivo target coverage amenable to once daily dosing and has advanced into human clinical studies to investigate safety and pharmacokinetics. |
2101524-34-7 |
DC65249 |
AN15368
Featured
AN15368 (AN 15368) is a small molecule prodrug activated by parasite carboxypeptidases to yield a compound that targets the messenger RNA processing pathway in Trypanosoma cruzi (T. cruzi), exhibits potent in vitro activity against T. |
2152662-92-3 |
DC60334 |
Sirpiglenastat (Synonyms: DRP-104)
Featured
Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response. |
2079939-05-0 |
DC65251 |
ENT-01
Featured
ENT-01 shows promise in the treatment of constipation in those with Parkinson's disease (PD) by preventing or reducing the formation of αS aggregates that form in enteric neurons. ENT-01 has undergone Phase 2b clinical trials to evaluate the safety and efficacy of the orally administered drug for the alleviation of constipation in those with PD. |
|
DC65252 |
compound 27
Featured
compound 27, is a potent (13 nM) CNS-penetrant compound that reduces very long chain fatty acid (VLCFA) levels in the CNS, which are believed to be pathological in the rare disease adrenoleukodystrophy (ALD). The starting point came from an HTS on compounds from an internal collection. |
|
DC65253 |
compound 14d
Featured
“Compound 14d” (Shionogi & Co.) is a highly potent, dose-dependent adenosine monophosphate activated protein kinase (AMPK) activator being investigated for its blood-glucose-lowering effects. |
|
DC65254 |
BI685509
Featured
BI685509 is a soluble guanylate cyclase (sGC) activator taken orally, with potential to treat diabetic and kidney diseases. In both rat and human platelets, BI685509 was found to restore/enhance cGMP, but had no effect on the functionality of nitric oxide pathways. BI685509 is currently undergoing phase 2 trials for the treatment of diabetic nephropathy, with the aim of improving kidney function. |
1579514-06-9 |
DC65255 |
DN-1289
Featured
DN-1289 is a potent and selective dual DLK/LZK inhibitor. DN1289 demonstrated excellent in vivo plasma half-life across species and is anticipated to freely penetrate the central nervous system with no brain impairment based on in vivo rodent pharmacokinetic studies and human in vitro transporter data. Proximal target engagement and disease relevant pathway biomarkers were also favorably regulated in an in vivo model of amyotrophic lateral sclerosis. |
|
DC65256 |
compound 6
Featured
“Compound 6” (Novartis) is a first-in-class YAP-TEAD protein-protein inhibitor. The TEAD transcription factor and its coactivator YAP and WWTR1/TAZ of the Hippo pathway are responsible for directly regulating the expression of genes involved in cell proliferation and organ size. |
|
DC65257 |
compound 29
Featured
Overcoming FGFR mutation resistance and FGFR1-mediated hyperphosphatemia toxicity through isoform-selective FGFR2/3 inhibition. “Compound 29” is an ATP-competitive fibroblast growth factor receptor (FGFR) 2/3 inhibitor with subnanomolar potency. |
|
DC60458 |
BI-3231
Featured
BI-3231 is a novel potent and selective HSD17B13 inhibitor with IC50 of 1 nM and Ki of 0.7 nM, respectively. BI-3231 is a valuable chemical probe to further elucidate the biological function of HSD17B13. |
|
DC60459 |
OICR-8268
Featured
OICR-8268 is a small molecule ligands that target DCAF1 and shows the highest affinity for binding to the DCAF1 WDR domain with SPR KD of 38 nM. OICR-8268 is an excellent tool compound to enable the development of next-generation DCAF1 ligands toward cancer therapeutics. |
|
DC65258 |
PUM00199
Featured
PUM00199, also known as PARP10-IN-3, is a selective mono‐ADP‐ribosyltransferase PARP10 inhibitor with an IC50 of 480 nM for human PARP10. |
2225800-19-9 |
DC65259 |
KR-32568
Featured
KR-32568 is an inhibitor of the sodium-hydrogen exchanger isoform-1 (NHE-1; IC50 = 230 nM). It restores cardiac contractile function ex vivo in an isolated ischemic rat heart model when used at a concentration of 10 μM. |
852146-73-7 |
DC65260 |
TCS-46b
Featured
TCS 46b is an orally active, subtype-selective GluN1A/GluN2B NMDA receptor antagonist |
302799-86-6 |
DC65261 |
SBS probe
Featured
SBS is a useful probe and tool molecule for detecting amyloid deposits in systemic amyloidosis in vitro and in vivo. SBS can be used for detecting amyloid fibrils in autopsy and biopsy samples from patients with localized amyloidosis, such as familial prion disease, and systemic amyloidosis, such as familial amyloidotic polyneuropathy, amyloid A (AA) amyloidosis, light chain (AL) amyloidosis, and dialysis-related amyloidosis. |
291766-06-8 |